IP Library Granted Patent US 9,810,610
Granted Patent B2
US 9,810,610 · App. 14/856,611 · Granted Nov 7, 2017

Method of partial lysis and assay

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,810,610
App. No.
14/856,611
Granted
Nov 7, 2017
Kind
B2
Abstract

The present disclosure describes a method of treating a sample comprising cells with a process of partial lysing. Cells are exposed to a process such as bead beating that lyses some cells in the mixture. The process generates a resultant sample mixture that is suitable for both cell morphology screening and genetic screening. A first portion of the partially lysed sample can be mounted on a slide and observed for atypical cells and cytologic abnormalities. A second portion of the partially lysed sample can be screened for genetic markers known to correlate with a risk of cervical cancer. The method is particularly useful for cervical screening, where a combination of cytology and genetic screening present a more complete picture of cervical health. The disclosed method streamlines the diagnostic process for protocols that require both types of assays, without compromising screening accuracy.

Claims (37)

1. A method of evaluating a biological sample comprising cells, said method comprising:

obtaining a biological sample from a subject;

contacting the biological sample with a biological sample preservative to create a preserved biological sample;

partially lysing the preserved biological sample to create a mixture comprising lysed cells, whole cells, and molecular components;

characterizing a first portion of the mixture using cell based analysis, wherein cell based analysis comprises mounting whole cells on a slide; and

assaying a second portion of the mixture for molecular components.

2. The method of claim 1 , wherein partially lysing comprises exposing the entire preserved biological sample to a lysing process.

3. The method of claim 1 , wherein less than 50% of cells are lysed.

4. The method of claim 1 , wherein partially lysing comprises mechanical shearing, detergent lysing, osmotic lysing, chemical denaturing, centrifuging, sonicating, freeze-thawing or a combination thereof.

5. The method of claim 4 , wherein mechanical shearing comprises syringe shearing, bead beating or a combination thereof.

6. The method of claim 1 , wherein the molecular components comprise components of a pathogen present in the biological sample.

7. The method of claim 6 , wherein the pathogen is associated with a disease selected from a group including chlamydia , gonorrhea, trichomoniasis, and candidiasis.

8. The method of claim 1 , wherein assaying comprises detecting nucleic acids, quantifying nucleic acids, identifying nucleic acids or sequencing.

9. The method of claim 8 , further comprising comparing an identified nucleic acid to a database of known markers to determine if the subject carries a known marker.

10. The method of claim 9 , wherein the known marker correlates with a risk of cancer.

11. The method of claim 9 , wherein the known marker is HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-68, HPV-73 or HPV-82.

12. The method of claim 1 , wherein cell based analysis comprises observing whole cells in the mixture.

13. The method of claim 1 , wherein the cell based analysis comprises screening cervical samples for squamous cell abnormalities or glandular cell abnormalities.

14. A method of evaluating a biological sample comprising cells, said method comprising:

obtaining a biological sample comprising cells from a subject;

contacting the biological sample comprising cells with a biological sample preservative to create a preserved biological sample;

containing the preserved biological sample in a vessel;

exposing the entire preserved biological sample in the vessel to a lysing process to create a mixture;

characterizing the mixture using cell based analysis, wherein cell based analysis comprises mounting whole cells on a slide; and

assaying the mixture for molecular components.

15. The method of claim 14 , wherein less than 50% of cells are lysed.

16. The method of claim 14 , wherein the lysing process comprises mechanical shearing, detergent lysing, osmotic lysing, chemical denaturing, centrifuging, sonicating, freeze-thawing or a combination thereof.

17. The method of claim 16 , wherein mechanical shearing comprises syringe shearing, bead beating or a combination thereof.

18. The method of claim 14 , wherein the mixture comprises whole cells, lysed cells, and molecular components.

19. The method of claim 18 , wherein the molecular components comprise components of a pathogen present in the biological sample.

20. The method of claim 19 , wherein the pathogen is associated with a disease selected from a group including chlamydia , gonorrhea, trichomoniasis, and candidiasis.

21. The method of claim 14 , wherein assaying comprises detecting nucleic acids, quantifying nucleic acids, identifying nucleic acids or sequencing.

22. The method of claim 14 , further comprising comparing an identified nucleic acid to a database of known markers to determine if the subject carries a known marker.

23. The method of claim 22 , wherein the known marker correlates with a risk of cancer.

24. The method of claim 23 , wherein the known marker is HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-68, HPV-73 or HPV-82.

25. The method of claim 14 , wherein cell based analysis comprises observing whole cells in the mixture.

26. The method of claim 14 , wherein the cell based analysis comprises screening cervical samples for squamous cell abnormalities or glandular cell abnormalities.

Assignments (6)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 036855/0468 Recorded Apr 24, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075456/0572 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 037448/0348 Recorded Apr 23, 2026
From: BANK OF AMERICA, N.A. AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED
Reel/Frame 075467/0587 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2017
From: SHUBER, ANTHONY P.; HECHT, STEVEN A.; COFFMAN, ERIN; MACLEAN, PAUL; KAUFMAN, HOWARD B.
To: HOLOGIC, INC.
Reel/Frame 042274/0809 →
SECURITY AGREEMENT Recorded Jan 6, 2016
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A. AS COLLATERAL AGENT
Reel/Frame 037448/0348 →
SECURITY AGREEMENT Recorded Oct 14, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LLC; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036855/0468 →